ASH 2021 Multiple Myeloma In-depth

PROMISE Study Provides ‘Most Precise’ Estimates of MGUS in High-Risk Patients

The incidence of MGUS was 17% among Black patients.

COVID-19 Vaccines Less Effective in Patients With Multiple Myeloma

Researchers observed a similar incidence of SARS-CoV-2 infections in vaccinated and unvaccinated patients with multiple myeloma.

CT103A Effective in MM Patients Who Failed Prior CAR T-Cell Therapy

CT103A yielded responses in patients who had received prior murine BCMA CAR T-cell therapy.

Study Supports Giving Daratumumab Upfront in Multiple Myeloma

Overall survival was longest with first-line daratumumab plus lenalidomide and dexamethasone.

Cilta-Cel Produces ‘Durable and Deep’ Responses in Relapsed/Refractory Multiple Myeloma

The stringent complete response rate increased from 67% at 1 year to 83% at 2 years.

‘High Prevalence’ of Smoldering Myeloma Observed in Nationwide Screening Study

More than one-third of patients had intermediate- or high-risk smoldering multiple myeloma.